Vanda Pharmaceuticals Inc.
Index- P/E30.54 EPS (ttm)0.32 Insider Own3.30% Shs Outstand56.10M Perf Week-3.90%
Market Cap541.80M Forward P/E56.59 EPS next Y0.17 Insider Trans-8.84% Shs Float54.48M Perf Month-10.84%
Income18.10M PEG0.85 EPS next Q0.11 Inst Own- Short Float7.69% Perf Quarter-26.40%
Sales266.20M P/S2.04 EPS this Y37.70% Inst Trans3.97% Short Ratio7.78 Perf Half Y-44.17%
Book/sh8.95 P/B1.07 EPS next Y-43.33% ROA3.10% Target Price10.00 Perf Year-46.14%
Cash/sh7.73 P/C1.25 EPS next 5Y36.10% ROE3.60% 52W Range9.24 - 21.86 Perf YTD-38.69%
Dividend- P/FCF9.25 EPS past 5Y27.80% ROI6.50% 52W High-56.00% Beta0.58
Dividend %- Quick Ratio5.40 Sales past 5Y13.00% Gross Margin90.50% 52W Low4.11% ATR0.47
Employees278 Current Ratio5.40 Sales Q/Q-4.00% Oper. Margin9.10% RSI (14)39.89 Volatility4.13% 5.05%
OptionableYes Debt/Eq0.00 EPS Q/Q-174.90% Profit Margin6.80% Rel Volume0.83 Prev Close9.74
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout0.00% Avg Volume538.26K Price9.62
Recom3.00 SMA20-3.19% SMA50-11.34% SMA200-34.58% Volume444,682 Change-1.23%
Feb-25-22Downgrade Jefferies Buy → Hold $24 → $12
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
May-19-22 07:00PM  
May-05-22 07:15PM  
May-04-22 04:30PM  
Apr-28-22 05:00PM  
Apr-27-22 03:03PM  
Mar-28-22 12:47PM  
Feb-23-22 04:01PM  
Feb-17-22 06:00PM  
Feb-09-22 12:25PM  
Feb-04-22 12:52PM  
Jan-26-22 10:48AM  
Jan-24-22 02:48PM  
Jan-21-22 05:38PM  
Jan-19-22 09:38AM  
Jan-18-22 02:41PM  
Jan-02-22 04:04PM  
Dec-08-21 11:34AM  
Nov-10-21 06:30PM  
Nov-03-21 10:01PM  
Oct-27-21 05:30PM  
Oct-23-21 06:08AM  
Oct-20-21 03:03PM  
Oct-15-21 12:09PM  
Oct-14-21 04:30PM  
Sep-21-21 12:00PM  
Sep-17-21 10:35AM  
Sep-07-21 08:30PM  
Aug-18-21 03:05PM  
Aug-10-21 06:30PM  
Aug-05-21 10:00AM  
Aug-03-21 01:22PM  
Jul-30-21 12:10PM  
Jul-29-21 12:32AM  
Jul-28-21 08:25PM  
Jul-26-21 04:07PM  
Jul-23-21 03:26PM  
Jul-21-21 04:30PM  
Jul-01-21 04:54AM  
Jun-30-21 07:42AM  
Jun-21-21 08:45PM  
Jun-08-21 03:16PM  
May-30-21 08:26PM  
May-12-21 04:30PM  
May-07-21 10:25AM  
May-06-21 09:53PM  
May-05-21 09:30PM  
May-04-21 07:30AM  
Apr-29-21 09:01PM  
Apr-28-21 12:34PM  
Apr-25-21 02:00AM  
Apr-20-21 04:30PM  
Apr-16-21 10:50PM  
Apr-13-21 08:15AM  
Apr-06-21 06:40AM  
Mar-23-21 07:15AM  
Mar-18-21 04:26PM  
Mar-17-21 01:56PM  
Mar-12-21 10:50PM  
Mar-11-21 01:52PM  
Feb-23-21 02:49PM  
Feb-14-21 01:32PM  
Feb-12-21 12:54AM  
Feb-11-21 10:28AM  
Feb-10-21 08:30PM  
Feb-02-21 04:30PM  
Dec-19-20 06:11PM  
Dec-02-20 03:02PM  
Dec-01-20 06:00PM  
Nov-17-20 12:43PM  
Oct-29-20 09:31AM  
Oct-28-20 05:55PM  
Oct-26-20 04:01PM  
Oct-21-20 04:45PM  
Oct-13-20 01:14PM  
Oct-02-20 01:44PM  
Aug-31-20 06:30PM  
Aug-18-20 10:24AM  
Aug-06-20 08:21PM  
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Birznieks GuntherSVP, Business DevelopmentMar 02Sale11.2711,517129,792188,807Mar 02 09:26 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale11.1529,588329,9451,352,766Mar 02 09:27 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 02Sale11.196,97478,060100,278Mar 02 09:28 PM
Williams TimothySVP & General CounselMar 02Sale11.0912,060133,779103,851Mar 02 09:29 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 02Sale11.288,83299,650119,691Mar 02 09:27 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 01Sale11.193,47338,863128,523Mar 02 09:27 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale11.197,50884,0151,382,354Mar 02 09:27 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale11.194,08445,700200,324Mar 02 09:26 PM
Polymeropoulos Mihael HristosPresident and CEODec 01Option Exercise4.8871,676349,7791,321,062Dec 02 04:31 PM
Polymeropoulos Mihael HristosPresident and CEODec 01Sale16.0046,200739,3481,274,862Dec 02 04:31 PM
Polymeropoulos Mihael HristosPresident and CEONov 30Option Exercise4.8878,324382,2211,299,386Dec 02 04:31 PM
Polymeropoulos Mihael HristosPresident and CEONov 30Sale16.4950,000824,2751,249,386Dec 02 04:31 PM
Jones Aranthan IIChief Corp. Affairs OfficerSep 15Option Exercise11.6612,119141,25098,804Sep 17 08:52 AM
Jones Aranthan IIChief Corp. Affairs OfficerSep 15Sale16.4916,824277,39481,980Sep 17 08:52 AM
Mitchell Stephen RayDirectorSep 09Option Exercise12.0319,109229,93628,324Sep 13 04:40 PM
Mitchell Stephen RayDirectorSep 09Sale16.7419,109319,9769,215Sep 13 04:40 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 20Sale15.393,65056,19074,552Aug 23 04:36 PM
Williams TimothySVP & General CounselAug 16Sale16.153,71559,98983,211Aug 17 04:31 PM
Moran Kevin PatrickSVP, CFO & TreasurerJul 28Sale19.242,13040,97399,296Jul 30 09:15 AM
Jones Aranthan IIChief Corp. Affairs OfficerJul 26Sale19.697,250142,77686,685Jul 27 04:37 PM
Chrousos PhaedraDirectorJun 14Sale19.342,07540,13212,925Jun 15 04:42 PM